Baqsimi is a drug owned by Amphastar Pharmaceuticals Inc. It is protected by 5 US drug patents filed from 2019 to 2025. Out of these, 4 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 23, 2039. Details of Baqsimi's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10765602 | Medication delivery systems and methods |
Sep, 2039
(12 years from now) | Active |
| US10894133 | Device for dispensing a fluid product |
Jan, 2038
(11 years from now) | Active |
| US10213487 | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(9 years from now) | Active |
| US12370241 | Nasal Powder Formulation For Treatment Of Hypoglycemia |
Feb, 2036
(9 years from now) | Active |
| US6938798 | Fluid or powdery product dispensing device |
Jan, 2022
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Baqsimi's patents.
Latest Legal Activities on Baqsimi's Patents
Given below is the list of recent legal activities going on the following patents of Baqsimi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 05 Aug, 2025 | US12370241 |
| Patent eGrant Notification | 29 Jul, 2025 | US12370241 |
| Mail Patent eGrant Notification | 29 Jul, 2025 | US12370241 |
| Patent Issue Date Used in PTA Calculation | 29 Jul, 2025 | US12370241 |
| Recordation of Patent eGrant | 29 Jul, 2025 | US12370241 |
| Email Notification | 29 Jul, 2025 | US12370241 |
| Email Notification | 17 Jul, 2025 | US12370241 |
| Issue Notification Mailed | 16 Jul, 2025 | US12370241 |
| Application Is Considered Ready for Issue | 27 Jun, 2025 | US12370241 |
| Dispatch to FDC | 27 Jun, 2025 | US12370241 |
FDA has granted several exclusivities to Baqsimi. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Baqsimi, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Baqsimi.
Exclusivity Information
Baqsimi holds 2 exclusivities out of which 1 have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Baqsimi's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2022 |
| New Patient Population(NPP) | Mar 17, 2028 |
Several oppositions have been filed on Baqsimi's European patents.
EP oppositions
can significantly impact the timeline for the generic launch of drugs. If an opposition results in the
revocation or
amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an
earlier entry
of generic versions into the market. To help you estimate the potential early arrival of Baqsimi's generic, the next section provides detailed information on
ongoing and past
EP oppositions related to Baqsimi patents.
Baqsimi's Oppositions Filed in EPO
Baqsimi has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 05, 2020, by Elkington And Fife Llp. This opposition was filed on patent number EP16710352A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP16710352A | Oct, 2020 | ELKINGTON AND FIFE LLP | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but
Baqsimi is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Baqsimi's family patents as well as insights into
ongoing legal events
on those patents.
Baqsimi's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Baqsimi:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Baqsimi's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 23, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Baqsimi Generic API suppliers:
Glucagon is the generic name for the brand Baqsimi. 4 different companies have already filed for the generic of Baqsimi, with Amphastar Pharms Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Baqsimi's generic
Alternative Brands for Baqsimi
Baqsimi which is used for treating severe hypoglycemia in patients with diabetes., has several other brand drugs using the same active ingredient (Glucagon). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Xeris |
| |||
| Zealand Pharma |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Glucagon, Baqsimi's active ingredient. Check the complete list of approved generic manufacturers for Baqsimi
About Baqsimi
Baqsimi is a drug owned by Amphastar Pharmaceuticals Inc. It is used for treating severe hypoglycemia in patients with diabetes. Baqsimi uses Glucagon as an active ingredient. Baqsimi was launched by Amphastar in 2019.
Approval Date:
Baqsimi was approved by FDA for market use on 24 July, 2019.
Active Ingredient:
Baqsimi uses Glucagon as the active ingredient. Check out other Drugs and Companies using Glucagon ingredient
Treatment:
Baqsimi is used for treating severe hypoglycemia in patients with diabetes.
Dosage:
Baqsimi is available in powder form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3MG | POWDER | Prescription | NASAL |